Low molecular weight heparins

Bibliography

• FREEDMAN JEAB: Pharmacology of heparin and oralanticoagulants. In: Thrombosis and hemorrhage. Loscalzo Jasai (Ed.), Blackwell Scientific Publications, Boston, MA, USA (19901155–1171.
   Google Scholar
• HIRSH J, LEVINE MN: LOW molecular weight heparin.Blood (1992) 79(0:1–17.
   PubMedGoogle Scholar
• FAREED J, JESKE W, HOPPENSTEADT D, CLARIZIO R,WALENGA JM: Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol (1998) 82 (5B) :3L–10L.
   Google Scholar
• WEITZ JI: low-molecular-weight heparins [publishederratum appears in N. EngL J. Med. (1997) 337(21):1567]. N Engli. Med. (1997) 337 (10):688–698.
   Google Scholar
• CHOAY J: Structure and activity of heparin and itsfragments: an overview. Haemostasis (1989) 15(0359–364.
   Google Scholar
• KLEIN W, BUCHWALD A, HILLIS SE et al.: Comparison oflow-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragrnin in unstable coronary artery disease study (FRIG) [published erratum appears in Circulation (1998) 97 (4):413]. Circulation (1997) 96 (1):61–68.
   Google Scholar
• LANE DA, DENTON J, FLYNN AM, THUNBERG L, LINDAHLU: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem.J. (1984) 218(3):725–732.
   PubMed Web of Science ®Google Scholar
• LANE DA, PEJLER G, FLYNN AM, THOMPSON EA, LINDAHL U: Neutralization of heparin-related saccha-rides by histidine-rich glycoprotein and platelet factor 4 [published erratum appears in J. Biol. Chem. (1986) 261 (28):13387]. J. Biol. Chem. (1986) 261 (9):3980–3986.
   Google Scholar
• WARKENTIN TE, LEVINE MN, HIRSH J et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular- weight heparin or unfractionated heparin. N Engl. J. Med. (1995) 332(20):1330–1335.
   PubMed Web of Science ®Google Scholar
• XIAO Z, THEROUX P: Platelet activation with unfrac-tionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation (1998) 97 (3):251–256.
   PubMed Web of Science ®Google Scholar
• HIRSH J: Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thr ombo embolism and unstable angina. Circulation (1998) 98(15):1575–1582.
   PubMedGoogle Scholar
• KEREIAKES DJ, FRY E, MATTHAI W et al.: Combinationenoxaparin and abciximab therapy during percuta-neous coronary intervention: NICE guys finish first. J Invasive. Cardiol. (2000) 12 (Suppl. A):1A–5A.
   Google Scholar
• FAREED J, WALENGA JM, WILLIAMSON K, EMANUELE RM,KUMAR A, HOPPENSTEADT DA: Studies on the antithrombo tic effects and pharmacokinetics of heparin factions and fragments. Haemostasis (1985) 11(0:56-74. TURPIE AG: Can we differentiate the low-molecular-weight heparins? Clin. Cardiol. (2000) 23 (Suppl. 1):14–17. LIBBY P: Molecular bases of the acute coronary syndromes. Circulation (1995) 91(10:2844-2850. FALK E, SHAH PK, FUSTER V: Coronary plaque disrup-tion. Circulation (1995) 92 (3):657–671. BADIMON L, BADIMON JJ, LASSILA R, HERAS M, CHESEBRO JH, FUSTER V: Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen Type I at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood (1991) 7 8 (2):423–434.
   Google Scholar
• HERAS M, CHESEBRO J, WEBSTER M et al.: Ilirudin,heparin and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation (1990) 82:1476–1484.
   Google Scholar
• OLER A, WHOOLEY MA, OLER J, GRADY D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA (1996) 276(10811–815.
   Google Scholar
• GURFINKEL EP, MANOS EJ, MEJAIL RI et al.: Lowmolecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischaemia. J Am. Coll. Cardiol. (1995) 26(2):313–318.
   PubMedGoogle Scholar
• FRAGMIN DURING INSTABILITY IN CORONARY ARTERYDISEASE (FRISC) STUDY GROUP: Low-molecular-weight heparin during instability in coronary artery disease. Lancet (1996) 347 (9000:561–568.
   PubMedGoogle Scholar
• FRAGMIN AND FAST REVASCULARISATION DURING INSTABILITY IN CORONARY ARTERY DISEASE. INVESTI-GATORS: Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. [published erratum appears in Lancet (1999) 354(9188):1478]. Lancet (1999) 35 4 (9180):701–707.
   Google Scholar
• COHEN M, DEMERS C, GURFINKEL EP et al.: Low-molecular-weight heparins in non-ST-segment elevation ischaemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus iv. unfrac-tionated heparin, in non-Q-wave Coronary Events. Am. J. Cardiol (1998) 82 (5B):19L–24L.
   Google Scholar
• GOODMAN S et al.: One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). Eur. Heart J. (1998) 50 (50):Abstract P477.
   Google Scholar
• ANTMAN EM, MCCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non -Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation (1999) 100(15):1593–1601.
   Google Scholar
• ANTMAN EM, COHEN M, RADLEY D et al: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11 B-ESSENCE meta-analysis. Circulation (1999) 100(15):1602–1608.
   Google Scholar
• FRAX.I.S. (FRAxiparine in Ischaemic Syndrome): Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. Eur. Heart J. (1999) 20(20:1553–1562.
   PubMedGoogle Scholar
• MONTALESCOT G, PHILIPPE F, ANKRI A et al.: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: benefi-cial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation (1998) 98 (4):294–299.
   PubMedGoogle Scholar
• ANDREOTTI F, RONCAGLIONI MC, HACKETT DR et al.:Early coronary reperfusion blunts the procoag-ulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J. Am. Coll Cardiol (1990) 16(7):1553–1560.
   PubMedGoogle Scholar
• CUCUIANU MP, MISSITS I, OLINIC N, ROMAN S: Increasedristocetin-co-factor in acute myocardial infarction: a Exp. Opin. Pharmacother. (2000) 1(6) component of the acute phase reaction. Thromb. Haemost. (1980) 43(1):41–44.
   Google Scholar
• MARGULIS T, DAVID M, MAOR N et al.: The vonWillebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb. Haemost. (1986) 55 (3):366–368.
   PubMedGoogle Scholar
• AL NOZHA M, GADER AM, AL MOMEN AK, NOAH MS,JAWAID M, ARAFA M: Haemostatic variables in patients with unstable angina. Int. J. Cardiol. (1994) 43 (3):269–277.
   PubMedGoogle Scholar
• MONTALESCOT G, ANKRI A, VICAUT E, DROBINSKI G, GROSGOGEAT Y, THOMAS D: Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation (1995) 92 (1):31–38.
   PubMedGoogle Scholar
• NESVOLD A, KONTNY F, ABILDGAARD U, DALE J: Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study. Thromb. Res. (1991) 64(5):579–587.
   PubMed Web of Science ®Google Scholar
• STRANDBERG LE, KAHAN T, LUNDIN P, SVENSSON J, ERHARDT L: Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Haemostasis (1996) 26 (5):247–257.
   PubMedGoogle Scholar
• HOLM HA, LY B, HANDELAND GF et al.: Subcutaneousheparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis (1986) 16 (Suppl. 2) :30–37.
   Google Scholar
• LOCKNER D, BRATT G, TORNEBOHM E, ABERG W, GRANQVIST S. Intravenous and sc. administration of Fragrnin in deep venous thrombosis. Haemostasis (1986) 16 (Suppl. 2):25–29.
   Google Scholar
• FROSTFELDT G, AHLBERG G, GUSTAFSSON G et al.: LOW molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II)." Am. Coll. Cardiol. (1999) 33 (3):627–633.
   Google Scholar
• ROSS A: A randomized comparison of LMWH and UFH adjunctive to t-PA thrombolysis and aspirin. 3-15-2000. Ref Type: Report
   Google Scholar
• DETRE K, HOLUBKOV R, KELSEY S et al.: Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The national heart, lung and blood institute registry. N Engl. J. Med. (1988) 318(5):265–270.
   PubMedGoogle Scholar
• ROUBIN GS, KING SB, III, DOUGLAS JS, Jr., LEMBO NJ, ROBINSON KA: --Ir.tracoronary stenting during percuta-n eo us transluminal coronary angioplasty. Circulation (1990) 81 (Suppl. 3):IV92–100.
   Google Scholar
• SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al: A comparison of balloon-expandable-stent implanta-tion with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl. J. Med. (1994) 331 (8):489–495.
   PubMed Web of Science ®Google Scholar
• FISCHMAN DL, LEON MB, BAIM DS et al.: A randomizedcomparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl. J. Med. (1994) 331 (8):496–501.
   PubMed Web of Science ®Google Scholar
• FAXON DP, SPIRO TE, MINOR S et al.: LOW molecularweight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation (1994) 90(2):908–914.
   Google Scholar
• GIMPLE LW, HERRMANN HC, WINNIFORD M, MAMMEN E:Usefulness of Sc. low molecular weight heparin (ardeparin) for reduction of restenosis after percuta-neous transluminal coronary angioplasty. Am. J. Cardiol. (1999) 83 (11) :1524–1529.
   Google Scholar
• LABLANCHE JM, MCFADDEN EP, MENEVEAU N et al.:Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine An gio p las tie Co r o n air e Tr an slum in ale. Circulation (1997) 96(10):3396–3402.
   Google Scholar
• KARRILLON GJ, MORICE MC, BENVENISTE E et al.:Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30- day clinical outcome of the French Multicenter Registry. Circulation (1996) 94(7):1519–1527.
   Google Scholar
• KARSCH KR, PREISACK MB, BAILDON R et al.: Lowmolecular weight hep arm n (revip arm) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfrac-tionated Heparin and Placebo-Controlled Evaluation. J. Am. Coll Cardiol (1996) 28(6):1437–1443.
   Google Scholar
• HULL RD, RASKOB GE, PINEO GF et al.: Subcutaneous low-molecular-weight heparin compared with continuous iv. heparin in the treatment of proximal-vein thrombosis. N Engl. J. Med. (1992) 326 (15):975–982.
   PubMedGoogle Scholar
• LEVINE M, GENT M, HIRSH J et al.: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl. J. Med. (1996) 334(11):677–681.
   PubMed Web of Science ®Google Scholar
• KOOPMAN MM, PRANDONI P, PIOVELLA F et al.: Treatment of venous thrombosis with iv. unfraction-ated heparin administered in the hospital as compared with Sc. low- molecular-weight heparin administered at home. The Tasman Study Group [published erratum appears in IV Engl. J. Med. (1997) 337(17):1251]. N Engl. J. Med. (1996) 334(11):682–687.
   Google Scholar
• THE COLUMBUS INVESTIGATORS: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl. J. Med. (1997) 337 (10):657–662.
   PubMed Web of Science ®Google Scholar
• GOULD MK et al.: Low-molecular-weight heparinscompared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. (1999) 130(10800–809. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• MARK DB, COWPER PA, BERKOWITZ SD et al.: Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation (1998) 97 (17):1702–1707.
   Google Scholar
• CALIFF RM, MARK DB: Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. Am. Heart J (1997) 134(5 Pt 2):S88–S96.
   Google Scholar
• COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl. J. Med. (1997) 337 (7):447–452.
   Google Scholar
• O'BRIEN BJ, WILLAN A, BLACKHOUSE G, GOEREE R, COHEN M, GOODMAN S: Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am. Heart J. (2000) 139 (3):423–429.
   PubMedGoogle Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT D, HUAN X, RACANELLI A: Comparative study on the in vitro and in vivoactivities of seven low molecular weight heparins. Haemostasis (1988) 18 (Suppl. 3) :3–15.
   Google Scholar
• BONEU B: Iipw molecular weight heparin therapy: Is monitoring needed? Haemostasis (1994) 72:330–334.
   Google Scholar